Marinomed Biotech AG

Marinomed Biotech, also registered as Marinomed Biotech AG, is a pharmaceutical firm. The company's headquarters is situated in Austria. It operates under the legal form of an Aktiengesellschaft within Austrian corporate law. Its activities are situated within the broader biopharmaceutical sector.

On 1 April 2025, Marinomed Biotech reported a cybercrime attack that led to an unauthorized transfer of approximately €677,000. The funds were sent to recipients located outside the European Economic Area. The company attempted to reverse the transaction and block the funds at the recipient bank, but these efforts were unsuccessful. In response, Marinomed Biotech filed criminal charges with the relevant authorities. The firm engaged external advisors to conduct a thorough investigation of the breach. Simultaneously, the company began assessing whether its existing insurance policies would cover the financial loss.

A second cyber incident was disclosed on 1 November 2025, involving a similar unauthorized transfer of roughly €677,000 to parties outside the EEA. As with the earlier event, attempts to recall or block the transferred funds proved unsuccessful. The company again filed criminal charges, enlisted external experts for investigation, and reviewed potential insurance coverage. Throughout both episodes, Marinomed Biotech's management has emphasized that the firm's liquidity position remains secure. The board of directors has affirmed that the company’s financial stability is not compromised by the cyber‑related losses.